LALPATHLAB - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 3.8
| Stock Code | LALPATHLAB | Market Cap | 27,559 Cr. | Current Price | 1,641 ₹ | High / Low | 1,804 ₹ |
| Stock P/E | 51.9 | Book Value | 148 ₹ | Dividend Yield | 0.86 % | ROCE | 29.4 % |
| ROE | 23.1 % | Face Value | 10.0 ₹ | DMA 50 | 1,552 ₹ | DMA 200 | 1,490 ₹ |
| Chg in FII Hold | -3.11 % | Chg in DII Hold | 2.17 % | PAT Qtr | 141 Cr. | PAT Prev Qtr | 113 Cr. |
| RSI | 58.2 | MACD | 23.4 | Volume | 2,36,765 | Avg Vol 1Wk | 21,16,774 |
| Low price | 1,272 ₹ | High price | 1,804 ₹ | PEG Ratio | 2.34 | Debt to equity | 0.08 |
| 52w Index | 69.4 % | Qtr Profit Var | -4.92 % | EPS | 30.3 ₹ | Industry PE | 47.7 |
Dr. Lal PathLabs shows strong fundamentals with excellent ROCE and ROE, low debt-to-equity, and consistent profitability. Technically, the stock is trading above both its 50 DMA and 200 DMA, with RSI at 58.2 and MACD positive, indicating bullish momentum. However, the high P/E ratio compared to industry average, elevated PEG ratio, and declining quarterly profit variation raise caution. Overall, it is a moderately strong candidate for swing trading with controlled upside potential.
💡 Optimal Entry Price: Around 1,600–1,620 ₹ (near support levels close to DMA 50).
📈 Exit Strategy: If already holding, consider booking profits near 1,750–1,780 ₹ (short-term resistance) or exit if price falls below 1,580 ₹ (support zone).
✅ Positive
- 📈 Strong ROCE at 29.4% and ROE at 23.1% show efficient capital use.
- 💰 Low debt-to-equity ratio of 0.08 ensures financial stability.
- 📊 PAT growth from 113 Cr. to 141 Cr. quarter-on-quarter.
- 📉 Price trading above DMA 50 and DMA 200, confirming bullish trend.
⚠️ Limitation
- 📉 High P/E ratio of 51.9 compared to industry average of 47.7.
- 📉 Elevated PEG ratio at 2.34 suggests valuation concerns relative to growth.
- 📉 Dividend yield at 0.86% is modest.
📰 Company Negative News
- 📉 Decline in FII holding (-3.11%) shows reduced foreign investor confidence.
- 📉 Quarterly profit variation (-4.92%) highlights earnings pressure despite sequential improvement.
🌟 Company Positive News
- 📈 Increase in DII holding (+2.17%) signals strong domestic institutional support.
- 📊 PAT improved significantly compared to previous quarter.
🏭 Industry
- 📊 Industry P/E at 47.7, slightly lower than Lal PathLabs’ 51.9, suggesting sector is moderately valued while the stock is expensive.
- 📈 Diagnostics and healthcare industry remains resilient with long-term demand growth.
📌 Conclusion
Dr. Lal PathLabs presents a moderately strong swing trade opportunity. Strong fundamentals, low debt, and bullish technicals are positives, but high valuation, declining FII interest, and earnings pressure limit upside. Entry is favorable near 1,600–1,620 ₹, with profit booking advised around 1,750–1,780 ₹. Risk management is essential due to valuation premium and profit variation.